New Breakthroughs in Pain Management for Veterans with Mild Traumatic Brain Injury: Nexalin Technology’s Gen-2 tACS Device Proves Promising in Clinical Trial

Mark White, CEO of Nexalin Technology, recently discussed the positive outcomes of a clinical trial involving their Gen-2 tACS device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI). The trial took place at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System, as well as various departments at UC San Diego.

The study aimed to address a pressing issue for both veterans and the general public: mTBI. This condition results in a range of physical, cognitive, emotional, and behavioral challenges. However, effective treatments for post-concussive symptoms (PCS) are scarce, and there is still much to learn about the underlying causes. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), making diagnosis and treatment even more complex.

The clinical trial was a randomized, double-blind, placebo-controlled study lasting eight weeks. Two groups were involved: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve treatment sessions over four weeks, followed by a four-week observation period to analyze outcomes.

The encouraging results of this study are especially notable given the extensive market potential for therapies addressing traumatic brain injuries. The Traumatic Brain Injuries Assessment Market is forecasted to exceed $7.2 billion by 2032, according to Global Market Insights. Nexalin’s innovative approach shows promise in meeting the needs of individuals coping with mTBI, potentially enhancing their quality of life and offering hope for more effective treatment options in the future.